Mice deficient in Vβ8+NKT cells are resistant to experimental hepatitis but are partially susceptible to generalised Shwartzman reaction

Clinical and Experimental Medicine

Volumn 7, Issue 1, 2007, Pages 30-38

  Habu, Y ^a   Shinomiya, N ^a   Kinoshita, M ^a   Matsumoto, A ^a   Kawabata, T ^a   Seki, S ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Galactosylceramide; Concanavalin A; Natural killer T cells; Shwartzman reaction; V 8+NKT cells

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CD1D ANTIGEN; CONCANAVALIN A; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 12; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; T CELL RECEPTOR VBETA8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE PREDISPOSITION; GENE; HEPATITIS; LIVER CELL; MONONUCLEAR CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SHWARTZMAN PHENOMENON; ANIMAL; ANIMAL HEPATITIS; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; DRUG EFFECT; GENETICS; IMMUNOLOGY; MOUSE MUTANT; NATURAL KILLER CELL; T LYMPHOCYTE SUBPOPULATION;

MUS;

ANIMALS; CONCANAVALIN A; GALACTOSYLCERAMIDES; HEPATITIS, ANIMAL; INTERFERON TYPE II; INTERLEUKIN-4; KILLER CELLS, NATURAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SHWARTZMAN PHENOMENON; T-LYMPHOCYTE SUBSETS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947529698     PISSN: 15918890     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10238-007-0122-2     Document Type: Article

References (58)

1. Makino Y, Koseki H, Adachi Y et al (1994) Extrathymic differentiation of a T cell bearing invariant V alpha 14J alpha 281 TCR. Int Rev Immunol 11:31-46
2. Lantz O, Bendelac A(1994) An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 180:1097-1106
3. Cui J, Shin T, Kawano T et al (1997) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors Science 278:1623-1626
4. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13:251-276
5. Hashimoto W, Takeda K, Anzai R et al (1995) Cytotoxic NK1.1 Ag+ alpha beta T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 154:4333-4340
6. Seki S, Hashimoto W, Ogasawara K et al (1997) Antimetastatic effect of NK1+ T cells on experimental haematogenous tumour metastases in the liver and lungs of mice. Immunology 92:561-566
7. Ogasawara K, Takeda K, Hashimoto W et al (1998) Involvement of NK1+ T cells and their IFN-gamma production in the generalized Shwartzman reaction. J Immunol 160:3522-3527
8. Heremans H, Van Damme J, Dillen C et al (1990) Interferon gamma, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. J Exp Med 171:1853-1869
9. Ozmen L, Pericin M, Hakimi J et al (1994) Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction. J Exp Med 180:907-915
10. Wysocka M, Kubin M, Vieira LQ et al (1995) Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 25:672-676
11. Inui T, Nakagawa R, Ohkura S et al (2002) Age-associated augmentation of the synthetic ligand-mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro. J Immunol 169:6127-6132
12. Nakagawa R, Inui T, Nagafune I et al (2004) Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide. J Immunol 172:6550-6557
13. Osman Y, Kawamura T, Naito T et al (2000) Activation of hepatic NKT cells and subsequent liver injury following administration of alpha- galactosylceramide. Eur J Immunol 30:1919-1928
14. Inui T, Nakashima H, Habu Y et al (2005) Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice. J Hepatol 43:670-678
15. Tiegs G, Hentschel J, Wendel A (1992) A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90:196-203
16. Mizuhara H, O'Neill E, Seki N et al (1994) T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 179:1529-1537
17. Mizuhara H, Uno M, Seki N et al (1996) Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology 23:1608-1615
18. Toyabe S, Seki S, Iiai T et al (1997) Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol 159:1537-1542
19. Hong S, Wilson MT, Serizawa I et al (2001) The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 7:1052-1056
20. Sharif S, Arreaza GA, Zucker P et al (2001) Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7:1057-1062
21. Miyamoto K, Miyake S, Yamamura T(2001) A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413:531-534
22. Morshed SR, Mannoor K, Halder RC et al (2002) Tissue-specific expansion of NKT and CD5+B cells at the onset of autoimmune disease in (NZBxNZW)F1 mice. Eur J Immunol 32:2551-2561
23. Zeng D, Liu Y, Sidobre S et al (2003) Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus. J Clin Invest 112:1211-1222
24. Matsuda H Watanabe N, Geba GP et al (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9:461-466
25. Habu Y, Seki S, Takayama E et al (2001) The mechanism of a defective IFN-gamma response to bacterial toxins in an atopic dermatitis model, NC/Nga mice, and the therapeutic effect of IFN-gamma, IL-12, or IL-18 on dermatitis. J Immunol 166:5439-5447
26. Kawano T, Cui J, Koezuka Y et al (1997) CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278:1626-1629
27. Smiley ST, Kaplan MH, Grusby MJ (1997) Immunoglobulin E production in the absence of interleukin-4-secreting CD1-dependent cells. Science 275:977-979
28. Mendiratta SK, Martin WD, Hong S et al (1997) CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4. Immunity 6:469-477
29. Chen YH, Chiu NM, Mandal M et al (1997) Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Immunity 6:459-467
30. Kawamura T, Takeda K, Mendiratta SK et al (1998) Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol 160:16-19
31. Carnaud C, Lee D, Donnars O et al (1999) Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 163:4647-4650
32. Kaneko Y, Harada M, Kawano T et al (2000) Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 191:105-114
33. Takeda K, Hayakawa Y, Van Kaer L et al (2000) Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci U S A 97:5498-5503
34. Dieli F, Sireci G, Russo D et al (2000) Resistance of natural killer T cell-deficient mice to systemic Shwartzman reaction. J Exp Med 192:1645-1652
35. Behlke MA, Spinella DG, Chou HS et al (1985) T-cell receptor beta-chain expression: dependence on relatively few variable region genes. Science 229:566-570
36. Behlke MA, Henkel TJ, Anderson SJ et al (1987) Expression of a murine polyclonal T cell receptor marker correlates with the use of specific members of the V beta 8 gene segment subfamily. J Exp Med 165:257-262
37. Kobayashi E, Motoki K, Uchida T et al (1995) KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7:529-534
38. Morita M, Motoki K, Akimoto K et al (1995) Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J Med Chem 38:2176-2187
39. Schumann J, Voyle RB, Wei BY, MacDonald HR (2003) Cutting edge: influence of the TCR V beta domain on the avidity of CD1d:alpha-galactosylceramide binding by invariant V alpha 14 NKT cells. J Immunol 170:5815-5819
40. Nakagawa R, Nagafune I, Tazunoki Y et al (2001) Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 166:6578-6584
41. Habu Y, Uchida T, Inui T et al (2004) Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment. Immunology 113:35-43
42. Gantner F, Leist M, Lohse AW et al (1995) Concanavalin A-induced T-cell-mediated hepatic injury in mice: the role of tumor necrosis factor. Hepatology 21:190-198
43. Minagawa M, Deng Q, Liu ZX et al (2004) Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology 126:1387-1399
44. Biburger M, Tiegs G (2005) Alpha-galactosylceramide-induced liver injury in mice is mediated by TNF-alpha but independent of Kupffer cells. J Immunol 175:1540-1550
45. Diao H, Kon S, Iwabuchi K et al (2004) Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21:539-550
46. Ohteki T, MacDonald HR (1996) Stringent V beta requirement for the development of NK1.1+ T cell receptor-alpha/ beta+ cells in mouse liver. J Exp Med 183:1277-1282
47. Kawamura T, Seki S, Takeda K et al (1999) Protective effect of NK1.1(+) T cells as well as NK cells against intraperitoneal tumors in mice. Cell Immunol 193:219-225
48. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV (2000) Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 192:921-930
49. Nakashima H, Inui T, Habu Y et al (2006) Activation of mouse natural killer T cells accelerates liver regeneration after partial hepatectomy. Gastroenterology 131:1573-1583
50. Anzai R, Seki S, Ogasawara K et al (1996) Interleukin-12 induces cytotoxic NK1+ alpha beta T cells in the lungs of euthymic and athymic mice. Immunology 88:82-89
51. Yumoto T, Dmochowski L (1967) Light and electron microscope studies of organs and tissues of SJL-J strain mice with reticulum cell neoplasms resembling Hodgkin's disease. Cancer Res 27:2098-2112
52. Merrill JE, Kono DH, Clayton J et al (1992) Inflammatory leukocytes and cytokines in the peptide-induced disease of experimental allergic encephalomyelitis in SJL and B10.PL mice. Proc Natl Acad Sci U S A 89:574-578
53. Yoshimoto T, Bendelac A, Hu-Li J, Paul WE (1995) Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc Natl Acad Sci U S A 92:11931-11934
54. Howard LM, Miga AJ, Vanderlugt CL et al (1999) Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 103:281-290
55. Akbari O, Stock P, Meyer E et al (2003) Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat Med 9:582-588
56. Lisbonne M, Diem S, de Castro Keller A et al (2003) Cutting edge: invariant V alpha 14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J Immunol 171:1637-1641
57. Morishima Y, Ishii Y, Kimura T et al (2005) Suppression of eosinophilic airway inflammation by treatment with alpha-galactosylceramide. Eur J Immunol 35:2803-2814
58. Hachem P, Lisbonne M, Michel ML et al (2005) Alpha-galactosylceramide- induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma. Eur J Immunol 35:2793-2802